Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark
in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of …

Extensive neuropathological studies have established a compelling link between
abnormalities in structure and function of subcortical monoaminergic (MA-ergic) systems …

Alzheimer disease (AD) is a medically and financially overwhelming condition, and
incidence rates are expected to triple by 2050. Despite decades of research in animal …

Alzheimer's disease is a progressive and irreversible neurodegenerative disease,
associated with a decreased cognitive function and severe behavioral abnormalities. Due to …

Latrepirdine (Dimebon TM) was originally marketed as a non-selective antihistamine in
Russia. It was repurposed as an effective treatment for patients suffering from Alzheimer's …

The etiology of common, nonfamiliar late-onset Alzheimer's disease (LOAD) is only partly
understood and seems to be extremely complex including many genetic and environmental …

The two major histopathologic hallmarks of Alzheimer's disease (AD) are amyloid beta
protein (Aβ) plaques and neurofibrillary tangles (NFT). Aβ pathology is a common feature in …

The mitochondria‐targeting drugs can be conventionally divided into the following groups:
those compensating for the energy deficit involved in neurodegeneration, including …

Dimebon (latrepirdine) is an anti-histaminergic agent which belongs to a fast-growing group
of “old” medicines suggested to be of therapeutic utility for pathological conditions different …

Multiple organ systems, including the brain, which undergoes changes that may increase
the risk of cognitive decline, are adversely affected by diabetes mellitus (DM). Here, we …